Insider Sales Highlight ORIC Pharmaceuticals' Stock Activity Recent insider transactions at ORIC Pharmaceuticals reveal a strategic reduction in holdings by executives, including CEO Jacob Chacko. These sales, totaling over 42,000 shares, come as the company continues to refine its clinical and financial strategies. Despite the insider activity, analysts maintain a positive outlook on the stock's long-term potential.56